Microbeam evolution: From single cell irradiation to pre-clinical studies by Ghita, Mihaela et al.
Microbeam evolution: From single cell irradiation to pre-clinical studies
Ghita, M., Fernandez-Palomo, C., Fukunaga, H., Fredericia, P. M., Schettino, G., Bräuer-Krisch, E., ... Prise, K.
M. (2018). Microbeam evolution: From single cell irradiation to pre-clinical studies. International journal of
radiation biology. https://doi.org/10.1080/09553002.2018.1425807
Published in:
International journal of radiation biology
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright 2018 Taylor & Francis. This work is made available online in accordance with the publisher’s policies. Please refer to any
applicable terms of use of the publisher.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:05. Apr. 2019
Microbeam evolution: From single cell irradiation to preclinical studies 
 
Mihaela Ghita1*, Cristian Fernandez-Palomo2, Hisanori Fukunaga1, Pil M. Fredericia3, 
Giuseppe Schettino4, Elke Bräuer-Krisch5, Karl T. Butterworth1, Stephen J. McMahon1 and 
Kevin M. Prise1  
 
(1)Centre for Cancer Research and Cell Biology, Queen’s University Belfast, 97 Lisburn 
Road, Belfast, BT9 7AE, UK (2) Institute of Anatomy, University of Bern, Baltzerstrasse 2 
CH-3000 Bern 9, Switzerland, (3) Centre for Nuclear Technologies, Technical University of 
Denmark, Frederiksborgvej 399, 4000 Roskilde, Denmark, (4)National Physical Laboratory, 
Hampton Road, Teddington, Middlesex, TW11 0LW. (5) European Synchrotron Radiation 
Facility, 71 Avenue des Martyrs, 3800, Grenoble, France. 
 
Keywords: Microbeam, DNA damage, MRT, bystander effects of radiation 
 
 
* Corresponding author 
Dr Mihaela Ghita 
Centre for Cancer Research and Cell Biology 
Queen’s University Belfast 
97 Lisburn Road 
BT9 7AE 
Belfast 
Northern Ireland, UK 
Tel: 0044 2890 972307 
Fax: 0044 2890 972776 
Email: m.ghita@qub.ac.uk 
 
 
 
Abstract 
 
Purpose 
This review follows the development of microbeam technology from the early days of single 
cell irradiations, to investigations of specific cellular mechanisms, to the development of new 
treatment modalities in vivo. A number of applications using microbeams are discussed with a 
focus on preclinical modalities and translation towards clinical application. 
Conclusions 
The development of radiation microbeams has been a valuable tool for the exploration of 
fundamental radiobiological response mechanisms. The strength of micro-irradiation 
techniques lies in their ability to deliver precise doses of radiation to selected individual cells 
in vitro or even to target subcellular organelles. These abilities have led to the development of 
a range of microbeam facilities around the world allowing the delivery of precisely defined 
beams of charged particles, X-rays, or electrons.  
In addition, microbeams have acted as mechanistic probes to dissect the underlying molecular 
events of the DNA damage response following highly localised dose deposition. Further 
advances in very precise beam delivery have also enabled the transition towards new and 
exciting therapeutic modalities developed at synchrotrons to deliver radiotherapy using plane 
parallel microbeams, in Microbeam Radiotherapy (MRT).  
 
 
 
 
 
 
1. Introduction 
Biological damage induced by ionising radiation occurs due to chemical changes caused by 
ionisation at the cellular level. The radiobiology paradigm is that nuclear DNA is the primary 
target for biological damage. The amount of biological damage induced by ionising radiation 
depends on variables including dose, the rate of absorption, the exposed area, and the variations 
in radical species, individuals sensitivity, and specific tissues and cells(Joiner & van der Kogel 
2009).  
Ionising radiation has been successfully exploited in radiotherapy as a powerful cancer therapy 
, which has been significantly refined due to the accumulation of knowledge on its effects 
derived from new advances in epidemiology and radiobiology (Clement et al. 2012). 
Continuous technological advances and new radiobiology challenges are behind the interest in 
the use of micro-irradiation techniques for radiobiological studies. Due to the very small beam 
size and high precision targeting within the cell, microbeams have empowered researchers with 
unique investigative methods. The technology has contributed significantly to the discovery of 
important novel time-sensitive interaction mechanisms of ionizing radiation with cells and 
tissues (Ghita et al. 2017; Walsh et al. 2017). In particular, the very precise dose delivery has 
played a fundamental role in the investigation of non-targeted effects where the radiation 
response is induced in cells which are not directly exposed to ionising radiation (Schettino et 
al. 2010). 
A number of technical features are vital to ensure that microbeams have the versatility and high 
specificity that is key for modern radiobiological experiments. These include:  the targeting 
accuracy, the particle counting efficiency, the dose rate and the rate at which cellular targets 
can be identified and irradiated.  A wide range of facilities have been developed worldwide 
delivering charged particles (ions including protons and helium ions), X-rays, and electrons for 
a number of specific in vitro and in vivo applications.  
Depending on the beam origin, the modern microbeams are divided into either cyclotron or 
accelerator based (for particle microbeams), compact X-ray source based (e.g. soft X-ray), and 
synchrotron based facilities.  
For basic radiobiological experiments where individual cells can be targeted, the key 
components of a microbeam are shown in figure 1 and include beam transport and microbeam 
producing devices, radiation detection, beam control, and cell dish design. These can be 
implemented in a number of different ways depending on the specific application of the facility. 
Microbeams are typically also equipped with an imaging station allowing the users to identify 
targets and align them with the radiation probe. They can also be used for following up cellular 
responses   the dynamics of cellular processes such as DNA damage and repair in real time. 
Imaging stations play a crucial role for microbeams in terms of identifying targets and aligning 
them with the radiation probe and following up cellular responses.  
Synchrotron based microbeams deliver X-rays emitted tangentially from relativistic electron 
bunches circulating in a storage ring. The irradiation modality consists an array of microbeams 
(25-100 m width), created by inserting a multi-slit collimator in the path of the high-flux 
Synchrotron X-Rays (Bräuer-Krisch et al. 2009; Bouchet et al. 2016; Smyth et al. 2016). 
For beam size adjustment, different methods to reduce the beam size are employed depending 
on the target. Cell dish design and particle detection are strongly dependent on the beam 
species, carefully considering beam orientation, any possible beam scatter around the dish or 
the very thin penetration depth of the particular beam. These aspects have been previously 
discussed in an in depth review on technical aspects of microbeams (Schettino et al. 2010).  
Microbeam facilities have been used in a variety of models to unravel some of the early events 
occurring immediately after the localized DNA damage within cells in vitro (Richard et al. 
2011). Recently, the technology has been used, under condition producing arrays of 
microbeams to elucidate bystander and abscopal effects in vivo (Fernandez-Palomo et al. 2015) 
progressing towards the development of novel radiotherapy modalities: microbeam radiation 
therapy (MRT) (Bräuer-Krisch et al. 2015). 
This review follows the development of microbeam technology from the early days of single 
cell irradiations to the development of new treatment modalities using microbeams focussing 
on preclinical developments and translation towards clinical applications 
2. Particle microbeams  
Microbeam approaches have been around since the early development of a UV microbeam by 
Tschachotin back in 1912 (Wu & Hei 2017). The first particle microbeam experiment was 
performed by Zirkle and Bloom in 1953 (Zirkle, Raymond & William 1953) using a 2 MV Van 
de Graaf accelerator to generate energetic protons. Micro-collimators consisting of two metal 
plates, with a grove etched on one of them, were clamped together to achieve a beam size of 
2.5 μm. This was used to study the process of cell division after proton exposure. From here, 
the development of modern microbeams has intensified in the early 1990’s, with the early 
developments using the cyclotron facility at the Brookhaven National Laboratories used to 
simulate the biological effects of cosmic ray. These first observations  of a dose-volume effect 
were the beginning of the later proposed MRT technique (W et al. 1959; Slatkin D N et al. 
1992). Another pioneer study used the 2 MeV Tandem accelerator-based microbeam at Pacific 
Northwest Laboratories (Braby 1991). 
Single cell charged particle microbeams can be grouped into two main categories according to 
the approach used to reduce the radiation beam to sub-cellular dimensions: microbeams using 
a collimation assembly and facilities employing electromagnetic focussing. 
Many of the early microbeams used collimation approaches, whereas more recently, 
electromagnetic focussing is  a more common approach reflecting both technological advances 
and the need for finer resolution probing micron level interactions within cells (Schettino et al. 
2010). 
Collimators and apertures have been extensively used at pioneering facilities of modern 
radiobiological microbeams, including Pacific Northwest Laboratory, Gray Cancer Institute 
and Columbia University. Using fused silica tubing with apertures as small as 1 μm diameters, 
90% protons and 99% 3He2+ were confined within a 2 μm spot (Folkard et al. 1997). Also laser 
drilled apertures of 5-6 μm were used to achieve 5 μm beams with 91% of non-scattered 
particles (Folkard et al. 1997). 
The electromagnetic focussing approach utilizes a variety of magnetic quadrupoles to obtain 
extremely narrow charged particle beams in vacuum. However, the focused beam has to be 
extracted in air, with a significant scattering being induced by the vacuum window, air gap and 
traversal of the cell support membrane.  
Electron microbeams rely on standard electron guns and electrostatic devices for beam 
generation. They produce and accelerate the energetic electron beams, which are subsequently 
reduced to micrometre size by the use of apertures or electromagnetic focusing (Sowa et al. 
2005). As scattering occurs when electrons interact with biological samples compared to 
heavier charged particles, it is challenging for electron microbeams to achieve targeting 
resolutions at the micron or submicron level despite the actual size of the focused beam. This 
poses challenges not only related to the resolution of electron microbeams but also to the 
calculation of the energy deposition and subsequent spatial dose distribution at the cellular 
level. These effects are not only significant for electron microbeams, but also for biological 
dosimetry of low energy electrons in general (Sowa et al. 2005; Siragusa et al. 2017).  
An updated overview of the facilities currently in operation, dedicated to biology or shared 
with analytical experiments, has recently been presented (Barberet & Seznec 2015) and an 
update is shown in table 1.  
 
3.  X-ray microbeams  
Considering the irradiation geometry, X-ray microbeams employ either a single beam or an 
array of microbeams. For cellular irradiation, single X-ray microbeams are used to specifically 
target subcellular compartments of the cells and analyse specific mechanisms behind cellular 
damage repair. However, there is growing interest in the preclinical setting of irradiation of 
tumours in vivo using arrays of microbeams with a more complex geometry and dose delivery. 
In addition to the beam geometry, the X-ray energy used and doses delivered will also vary 
between these two different types of microbeams (Folkard et al. 2001a) (Bouchet et al. 2010). 
An updated list of soft X-ray and synchrotron microbeam facilities is presented in table 2.  
Single X-ray microbeams have been developed, starting in the 1990s (Prise et al 1998), to 
provide quantitative and mechanistic radiobiological information to complement the charged 
particle studies. Damage caused by X-ray delivered to a single cell is qualitatively different 
than lesions produced by charged particles due to reduced clustering of the ionizations (Folkard 
et al. 1997). As scattering is not as important, X-ray microbeams are, in theory, capable of 
achieving radiation spots of an order of magnitude or smaller than those achieved with ion 
beams. Moreover, such high spatial resolution is maintained as the X-ray beam penetrates 
through cells making it possible to irradiate deeper targets with micron precision, making its 
therapeutic use feasible. Modern X-ray microbeams employ benchtop based electron 
bombardment X-ray sources for energies from 278 eV to 4.5 keV (Schettino et al. 2000). In 
addition to characteristic radiation, the electron bombardment of the target will produce a 
continuum of bremsstrahlung with a maximum energy equivalent to the energy of the incident 
electrons. This radiation is undesirable because it will not be focused correctly by the zone 
plate, and can be significantly more penetrating than the characteristic X-rays. The 
bremsstrahlung component is removed by reflecting the radiation off a silica mirror mounted 
between the target and the focusing assembly (Schettino et al. 2000)  For this type of soft X-
ray microbeams very small probes can be achieved by the use of X-ray optics developed for 
high-resolution X-ray microscopic imaging. The finest X-ray probes have been obtained using 
zone plates. These are circular diffraction gratings with radially increasing line densities, in a 
fashion that  brings the diffracted X rays to an axial focus (Folkard et al. 2001a). As with other 
diffraction devices, several diffracted orders are produced, and the unwanted orders must be 
prevented from reaching the cells, because they will not be appropriately focused. To do this, 
an arrangement of masks is used that allows only the first-order diffracted X-rays to reach the 
target. An important challenge when employing low energy microbeams is the attenuation in 
air requiring a very delicate dish design (Schettino et al. 2000).  
Alongside the self- contained design of these devices, the advantage of electron and X-ray 
microbeams lies in the ability to easily vary the beam energy and therefore the LET. This 
develops the spectrum of investigations in the context the relative biological effect for different 
energies. In this respect, electron and X-ray microbeams complement the work done with 
charged particle facilities to investigate the LET dependence(Folkard et al. 2001b; Wu & Hei 
2017). 
Synchrotron microbeams use energies in the range of 2.34-600 keV (Crosbie et al. 2015; 
Kaminaga et al. 2016). The beamlines use a bending magnet (for 2.34 keV) or a wiggler (30-
600 keV) to produce a virtually parallel beam of X-ray with minimal vertical divergence. This 
is then spatially fractionated using collimators and arranged in an array of alternating parallel 
micro-planar beams and gaps. This segments a high flux X-ray beam from a synchrotron into 
a micro-planar lattice of narrow beams, typically 25-50 μm wide and centre-to-centre 
separations of 200 or 400 μm. These can then potentially be cross-fired providing a large array 
of options for novel treatment modalities (Bouchet et al. 2010; Crosbie et al. 2010). This unique 
spatial distribution allows the delivery of an array of peak and valley doses. The former is 
directly deposited on the target by the microbeam while the latter is deposited in the tissue 
between the beams by scattered photons (Blattmann et al. 2005). The dramatic dose difference 
between heavily (peaks) and lightly (valleys) irradiated tissue, promoted when a broad beam 
is converted into an array of microbeams, is a very important synchrotron microbeam specific 
characteristic. The peak dose delivered is typically up to 300-800 Gy at the skin-entry level, 
valley doses of 12-20 Gy  and mean dose rates are in the range of thousands Gy s-1 (Crosbie et 
al. 2010; Bräuer-Krisch et al. 2015).  A schematic representation of a typical dose distribution 
for MRT is shown in figure 2.  
This setup has been used to irradiate cells, tissue and small to medium sized animals in an 
experimental technique known as microbeam radiation therapy (MRT). MRT has shown to 
have a preferential killing effect on tumour cells, which has been widely demonstrated in 
glioma models (Fernandez-Palomo et al. 2015; Smyth et al. 2016). Hypotheses for the efficacy 
of MRT due to the periodically alternating dose distribution are based on observations 
including the preferential damage to tumour microvasculature compared to normal brain 
microvasculature in vivo (Bouchet et al. 2010; Bouchet et al. 2016); in-field bystander effects 
related to cellular migration in vitro and in vivo (Crosbie et al. 2010; Bouchet et al. 2017) and 
the communication of stress factors in vitro between peak and valley regions (Smyth et al. 
2016). Research has also revealed that MRT seems to modulate the immune system by 
regulating the expression of growth factors, cytokines and lymphokines (Bouchet et al. 2013) 
and the recruitment of tumour-associated immune cells (Yang et al. 2014). 
 
4. Microbeam dosimetry challenges 
A key feature of the modern microbeam facilities is the ability to establish a priori an accurate 
reproducible dose that will be delivered to each sample. By coupling this with a high efficiency 
detection system, doses can be precisely monitored and  controlled by very fast beam shuttering 
or deflection system (Folkard et al. 1997).  
Particle detection characteristics can separate microbeams into two categories based on 
whether the detection occurs before or after the particles reach the biological sample ( Schettino 
et al. 2010). By placing the detector between the vacuum window and the sample holder, no 
further constraints are imposed on the sample holder or the cell environment. However, the 
inevitable detector-beam interaction reduces the quality and accuracy of the exposure. In order 
to minimise the energy loss in the detector, only thin, transmission type detectors are 
appropriate. These detectors are generally thin film plastic scintillators whose light flashes 
generated by the particles traversal are collected by a photomultiplier, and processed into 
individual particle counts (Folkard et al. 1997). 
An alternative configuration consists of placing the detector behind the sample holder. Using 
this approach, no extra scattering is introduced by the detector and better targeting accuracy 
can be reached (Mosconi et al. 2011). While conventional solid state detectors can be used 
(Sinenian et al. 2011), this configuration requires that the delivered particles have enough 
energy to pass through the samples, setting a limit of the lowest usable energy. In many cases 
it is also necessary to remove the culture medium requiring additional procedures to keep cells 
viable during the irradiation process (Sinenian et al. 2011). 
Due to the small radiation beam and the localized delivering of the radiation dose, conventional 
dosimetry approaches are not always relevant for microbeam exposures when used for single 
cell or sub-cellular targeting. The dosimetry for the microbeam facilities is usually reported in 
terms of the number of specific photons/ions delivered to a specific biological target. This 
depends on the particle species, energy along with detector efficiency and geometric 
characteristics of the cell (Folkard et al. 2001b). The timescale throughout which the radiation 
is delivered is also an important parameter, particularly for new radiation sources able to deliver 
high fluxes of radiation.  
However, the number of particles (or photons) delivered to the target of interest is only the first 
dosimetric measurement which has its main advantages in a direct and relatively 
straightforward comparison of the samples irradiation record. Such approaches have also been 
very useful in establishing the radiation risks related to the crossing of a single alpha particle 
(Miller et al. 1999). In order to relate the radiation responses measured with microbeams to 
conventional radiation exposures, it is important to estimate the energy deposited in individual 
cells or specific sub-cellular target. Such calculations require the number of radiation events 
experienced by the cell together with information about the cell geometry and radiation energy. 
Monte Carlo calculations have also been employed for such estimations (Miller et al. 1999). 
Difficulties in defining the volume (and therefore mass) of interest makes it hard to report such 
dosimetry assessment in terms of macroscopic dose measurements (i.e. Gy) and has led to 
definition of parameters such as ‘specific dose’ which characterises the dose deposited in 
specific cellular sub-components (Randers-Pehrson 2002).  
The dosimetry for synchrotron based microbeams is more complex and requires aspects of 
spectrum verification (Crosbie et al. 2015) and absolute dose measurements at ultra-high dose 
rates (Fournier et al. 2016). Standard protocols for high resolution Gafchromic film 
measurements in combination with microscopy have been used with an accuracy of better than 
5% for the peak dose and between 10% and 15% for the valley doses (Bartzsch et al. 2015; 
Bräuer-Krisch et al. 2015). For MRT, the dose to a large macroscopic volume is usually 
reported together with information about the size of the microbeams, the gap between the 
microbeams and the ratio of peak-to-valley dose (i.e. dose in the centre of microbeam compared 
to dose in the gap between the microbeams). Assessment of the dose in such a small volumes 
is challenging and requires dedicated protocols and tools. A variety of detectors have been 
investigated for dosimetry assessment in synchrotron microbeams  with each presenting both 
limitations and advantages(Bräuer-Krisch et al. 2010), (Alagoz et al. 2016), (Gagliardi et al. 
2015), (Okada et al. 2011).  
 
5. Cellular and tissue effects  
The main focus of research conducted into the effects of ionising radiation on cells has focused 
on the damage to the cell nucleus and the detrimental effects this has on the cell. The prevailing 
acceptance in radiation biology and radiotherapy is that a high enough dose of energy deposited 
to the nucleus will ultimately lead to cell death. Within this dogma, the cytoplasm, the cellular 
environment in which most of the cellular processes take place have rarely been taken into 
account. With the developing microbeam facilities, the role of cytoplasm in radiation-induced 
biological responses became increasingly important in cytoplasm targeted reactions (Walsh et 
al. 2017), bystander cellular responses, (Tartier et al. 2007) and in interactions with gold 
nanoparticles (Ghita et al. 2017). 
 
Subcellular Targeting 
The strength of the micro-irradiation technique lies in its ability to deliver precise doses of 
radiation to selected individual cells in vitro or to preselected targets within cells. The 
development of microbeams has allowed further dissection of cellular and molecular events in 
various experiments for DNA damage and repair (Kashino et al. 2004; Tartier et al. 2007; 
Richard et al. 2011; Ghita et al. 2017; Walsh et al. 2017). These studies have made use of the 
microscopy advances as well to quantify the radiation induced stress at different subcellular 
levels. This has made a significant impact on the understanding of mechanistic radiation 
responses in cells.  
Microbeam technology has led the way to further innovation investigating cellular targeting 
and responses in cells but other approaches have played a role. For example studies using Auger 
electron emitters targeted to different cellular compartments tested the potential for inducing 
non-targeted effects. The induction of these effects was found to be equally potent whether the 
Auger emitter was located on the cell membrane, in the cytoplasm or in the nucleus of the 
donor cells (Paillas et al. 2016). Although most of these studies agree on DNA being the most 
radiosensitive target, other cellular compartments especially the cell membrane also seem to 
be involved in both effects (Kassis 2004; Pouget et al. 2008; Kassis 2011; Paillas et al. 2016). 
During the past 10 years, there has been a shift away from a totally DNA-centric approach to 
include models that invoke complex signalling pathways in cells and between cells within 
tissues. Several newly recognised responses have been classified as so-called non-targeted 
responses (Tartier et al. 2007) in which biological effects are not directly related to the amount 
of energy deposited in the DNA of the cells traversed by the radiation.  
 
Intercellular Communication 
A major shift in our thinking about radiation effects has taken place with the finding that non-
irradiated cells can respond biologically when their neighbours are irradiated, referred to as 
bystander responses. The ability to select individual cells or regions of tissues for localized 
irradiation is key to determining the role of intra- and intercellular signalling, and in depth 
reviews have been focusing on this aspect for in vitro work (Prise et al. 2010; Prise et al 1998; 
G Schettino et al. 2010).  
A recent study investigated the cell death and cell-cycle arrest of microbeam-irradiated cells 
and adjacent non-irradiated bystander cells in a human HeLa-Fucci spheroid culture with time-
lapse imaging (Kaminaga et al. 2016). To our knowledge, this was the first real-time imaging 
of the dynamics of microbeam-irradiated and non-irradiated bystander cells. This was further 
developed in a study showing radiation-induced pro-inflammatory responses, including 
signalling in the NF-κB-COX-2 pathway, in a human 3-D organotypic skin culture exposed to 
modified X-ray fields (Acheva et al 2017).  
Advanced Tissue Models 
Extending the present two-dimensional (2D) cell culture results to more complex models has 
been an important development area for microbeam research. In recent years, 3D culture 
methods, such as spheroid cultures (i.e., small aggregates of cells growing free of foreign 
materials) (Fennema et al. 2013; Ishiguro et al. 2017) and organoid technologies (i.e., stem 
cell-derived 3-D cultures) (Lancaster & Knoblich 2014), have been developed to preserve the 
biological characteristics of the original tissues or organs better than conventional 2D 
monolayer cultures. This progress could contribute to the elucidation of the molecular 
mechanisms of radiation-induced bystander responses at the tissue level and has potential for 
the development of new diagnostic and therapeutic radiation techniques (Belyakov et al. 2001; 
Belyakov et al. 2006), (Buonanno et al. 2015; Peng et al. 2017).  
More in vivo-like culture methods, such as ex vivo tissue and organ cultures, also have potential 
as useful tools for microbeam research. Organotypic tumour tissue slice methods optimized for 
ex vivo culture would be useful for assessing not only tumour-specific drug responses but also 
microbeam-induced bystander responses (Vaira et al. 2010; Naipal et al. 2016). Some ex vivo 
organ culture techniques (e.g., human hair follicle (Langan et al. 2015), mouse testis (Sato et 
al. 2011)) are likely to be applicable to microbeam research.  
Preclinical applications of MRT 
Finally, moving beyond mechanistic studies, synchrotron MRT has shown high therapeutic 
potential in small animal models of malignant brain tumours with a preferential effect on 
intracerebral 9L gliosarcoma vascular networks (Bouchet et al. 2010; Crosbie et al. 2010) with 
the resulting survival data presented in Figure 4. In this context a recent study (Fernandez-
Palomo et al. 2015) interrogated γH2AX as a biomarker for dose deposition in the brain after 
synchrotron microbeam irradiation. This study shows a direct correlation between the 
irradiation dose and induced foci for entry doses up to 350 Gy. Furthermore, a correlation 
between the microbeam foci track width and dissection time at the highest dose with no 
significant change in the width of the microbeam tracks at lower irradiation doses. This 
suggests that the radiation induced bystander effect has an impact on the cells reached by both 
the high-peak doses and the dose gradient of the transition zone (Fernandez-Palomo, Bräuer-
Krisch, et al. 2015).  
Several groups have now extended studies from cell culture models to in vivo systems using 
synchrotron microbeams. A microscopy image of cross-fired microbeams is shown in figure 
2a as a 2D slice, or a 3D volume at different magnifications in 2b and 2c (Gagliardi et al. 2015). 
Different DNA damage patterns after irradiation with 2 Gy using C soft X-ray of a 2D 
monolayer is shown in figure 3a and 3b. In an in vivo setup, DNA damage induced after 
synchrotron irradiation of mouse cerebellum with an entry-dose of 350 Gy is shown in figure 
3b, 3c and 3d (Fernandez-Palomo et al. 2015).   
 
 
 
6. Clinical translation for therapy developments 
Microbeam radiation therapy (MRT), an innovative pre-clinical radiotherapy technique using 
spatially fractionated synchrotron X-rays, has been shown to spare radiosensitive tissues such 
as mammal brains (Serduc et al. 2008; Bouchet et al. 2016). In MRT the tumour is irradiated 
by arrays of micrometre wide planar beams of unconventionally high doses of up to a few 
hundred Gy that are separated by several hundred micrometre wide low dose regions (Bräuer-
Krisch et al. 2005). The major benefit of MRT over conventional radiotherapy approaches is 
associated with the dose volume effect where the utilization of a micrometre-scale treatment 
beam width leads to a higher radiation tolerance of normal tissue compared to tumour tissue 
(Bouchet et al. 2010), (Schültke et al. 2017; Serduc et al. 2008). Pre-clinical studies have 
demonstrated this advantage in several animal models, such as weanling piglets , duck embryos 
, and suckling and adult rats (Slatkin et al. 1995; Laissue et al. 1999; Dilmanian et al. 2002; 
Dilmanian et al. 2003; Dilmanian et al. 2005; Serduc et al. 2009; Van Der Sanden et al. 2010; 
Laissue et al. 2013; Bouchet et al. 2014). The skin has also been shown to tolerate very well, 
doses of 835-1335 Gy, which are far above of those used in pre-clinical studies (350 Gy) 
(Zhong et al. 2003). Moreover, the acute effects on skin produced by high MRT doses were 
similar to the effects of low doses of broad beam (Priyadarshika et al. 2011). Thus, the organ 
tolerance, particularly of the normal brain, could allow re-irradiation of the tumour. 
MRT in small animal models has achieved therapeutic ratios clearly exceeding those obtained 
by homogeneous dose distributions delivered using conformal preclinical radiotherapy in a 
range of malignancies (Grotzer et al. 2015). Currently, the production of clinical microbeams 
can only be facilitated at large synchrotron facilities like the European Synchrotron (ESRF) in 
Grenoble and the Imaging and Medical Beamline (IMBL) at the Australian Synchrotron, due 
to the high beam flux and quality requirements. However, the possibility to use a conventional 
X-ray tube or carbon nanotubes (S. Wang et al. 2011) to produce microbeams for preclinical 
studies has also been explored. This study used an X-ray tube with a small focal spot and a 
specially designed collimator were used to produce microbeams for preclinical research 
(Bartzsch et al. 2016).  
The growing interest in bright monochromatic and tuneable X-ray sources for use in imaging 
and radiation therapy has led to the collaboration of seven research institutes and industry 
partners also known as the ThomX project, a compact Compton Backscattering Source (CBS) 
based in Orsay – France (Variola et al. 2014). The project aims to provide a fully operational 
hard X-ray CBS upgradable to be operated with a relatively reduced cost(Alagoz et al. 2016). 
Another recent study proposes other novel technical solution of line focus X-ray tubes, with 
the aim of clinical translation of MRT (Bartzsch & Oelfke 2017). Long term, this might enable 
the development of clinical microbeams without the need of a synchrotron.  
Various biological mechanisms have been suggested to explain MRT’s effectiveness. Strong 
evidence indicating that blood vessels and their different repair efficiencies in malignant and 
healthy tissue being essential to explain the microbeam differential effect (Bouchet et al. 2010). 
Given the clinical potential of MRT, robust normal tissue toxicity data, especially pre-clinical 
depth-dose data, must be collected in order to successfully translate these therapies to human 
clinical trials. While previous work employed computational modelling (Merrem et al. 2017), 
a lack of robust reference data means that further experimental studies on the geometric 
properties of the vascular networks are necessary to improve the predictions of the model. 
Previous reviews summarized the available normal tissue toxicity data from MRT animal 
studies and have considered how there relate to current normal tissue toxicity data and clinical 
dose constraints (Smyth et al. 2016). Furthermore, a novel treatment planning environment for 
synchrotron MRT has been developed based on the Eclipse ™ treatment planning system 
(Poole et al. 2017). This is an essential step in MRT progression towards human clinical trials. 
It is necessary that MRT not only meets current clinical standards but also has similarity with 
all stages of the radiotherapy process (Grotzer et al. 2015).  
As part of the MRT clinical prospects, Grotzer et al discussed the candidate populations for 
potential clinical trials. They identified two targets in adults with glioblastoma multiforme and 
in paediatric patients with diffuse intrinsic pontine glioma (Grotzer et al. 2015).  
The phase 1 clinical trials in Synchrotron Stereotactic Radiotherapy (SSRT) have allowed the 
community to move forward with synchrotron based therapies requiring the implementation of 
a small hospital like environment at the biomedical beamline ID17 at the European synchrotron 
Radiation Facility (ESRF) in Grenoble, France. With the SSRT clinical trial it will be possible 
to refine a protocol for dose enhancement using high Z elements in combination with low 
energy synchrotron X-rays. This can also be further exploited to improve the tumour control 
probability (TCP) in MRT (Bräuer-Krisch et al. 2015; Grotzer et al. 2015).  
 
7. Summary and future directions 
Microbeams have played a pivotal role in radiobiology. In its early days, the technology aimed 
to explore the basic radiobiological effects after cellular irradiation. With the ongoing evolution 
of the field, microbeams have refined to assess a range of responses after irradiation with X-
ray or charged particles. The main strength of the technology, the very controlled irradiation of 
a micron-sized areas of tissue, has initiated novel research avenues beyond the investigation of 
the underlying mechanisms of radiotherapy. Since the first reports using very small targeted 
radiation beams, the theoretical possibility of radiosurgery by irradiating parallel arrays of 
micro slices and cross firing the array through the tumours from several ports has attracted the 
attention of several groups internationally. Microbeams technology has also served as the 
underpinning for MRT - a technique with the potential to impact the clinical landscape. 
While the MRT concept has also been extended to proton  heavy ion therapies, the development 
towards its clinical implementation is still a focus of radiation therapy programmes aiming 
towards its integration in the hospital environment (Bravin et al. 2015). With the increased 
number of potential applications of these technologies, novel technical and medical physics 
developments are key to further implement these methods into a clinical environment.  
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Figure 1 Key accessories for a single cell irradiation a microbeam  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Calculated lateral normalized dose profile for classical microbeam irradiation showing very steep dose gradients 
between peak doses and low doses delivered in the dose‐valley regions.  
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Table 1 Updated list of particle microbeam facilities after (Barberet & Seznec 2015) 
Facility  Particle  Energy Range  Reference 
RARAF Columbia 
University 
Protons, α  1‐5 MeV  Randers‐Pehrson et al 1996 
(Buonanno et al. 2015) 
SPICE NIRS Chiba  Protons  3.4 MeV  Konishi et al 2013 (Konishi et 
al. 2013) 
Ion Beam Centre Surrey   Protons, α, up to Ca  1‐12 MeV   Merchant et al 2012 
(Merchant et al. 2012) 
IMP Fudan  Protons, α  6 MeV   Wang et al 2011 (X.F. Wang et 
al. 2011) 
CENBG Bordeaux  Protons, α  1‐3.5 MeV  Bourret et al 2014 (Bourret et 
al. 2014) 
PTB Braunschweig  Protons, α  2‐20 MeV  Mosconi et al 2011 (Mosconi 
et al. 2011) 
Patrono et al 2015 ((Patrono 
et al. 2015) 
RIKEN Wako  Protons, α  3‐4 MeV  Iwai et al 2008 (Iwai et al. 
2008) 
SNAKE Munich  Protons, α, Li, O, Si, 
Cl, I 
4‐28 MeV 
1‐10.5 MeV u‐1 
Hauptner et al 2004 (Dollinger 
et al. 2005) 
Drexler et al 2015 (Drexler & 
Ruiz‐Gómez 2015) 
GSI Darmstadt  Protons, α, C to U  1.4‐11.4 MeV u‐1  Heiss et al 2006 (Heiss et al. 
2006) 
Jaeri Takasaki   Α, C, Ne, Ar  12.5‐17.5 MeV u‐1  Funayama et al 2005 
(Funayama et al. 2005) 
Leipzig  H, He  2.25 MeV  Butz el al 2000 (Butz et al. 
2000) 
 
 
 
 
Table 2 An updated list for X‐ray microbeam facilities 
Facility  Energy Range  Reference 
Columbia University   Ti soft X‐ray 4.5 
keV 
Harken et al 2011 (Harken et al. 
2011) 
Brookhaven National 
Laboratory 
2.584 GeV  Dilmanian et al  2001 
(Dilmanian et al. 2003) 
Queen’s University Belfast   K‐shell C soft X‐
ray 287 eV 
 Folkard et al 1997 (Folkard et 
al. 2001b) 
M. Ghita et al 2017 (Ghita et al. 
2017) 
European Synchrotron (ESRF), 
Grenoble 
27‐600 keV  Alagoz et al 2016 (Alagoz et al. 
2016) 
Australian Synchrotron 
Imaging and Medical Beamline 
(IMBL) 
125 keV  Crosbie et al 2010 (Crosbie et 
al. 2010) 
Gagliardi et al 2015 (Gagliardi 
et al. 2015) 
Institute of Cancer Research  225 kVp  Bartzsch et al 2016 (Bartzsch et 
al. 2016) 
KEK IMSS Photon Factory  2.34 keV  Kaminaga et al 2016 (Kaminaga 
et al. 2016) 
 
 
Electron microbeam 
Pacific Northwest 
National Laboratory  
Electrons  Variable energy  Sowa et al 2005 (Sowa et al. 
2005) 
 
 
 
 
 
Figure 3 Different magnitude of biological effects measured using γH2AX used as a DNA damage marker after microbeam 
irradiation using C K‐shell Soft X‐ray used a) in scanning mode and b) with a dose of 2 Gy delivered to cell nucleus; 
synchrotron X‐ray used to target the cerebellum in c) and d), with an entrance dose of 350 Gy  
 
 
 
 
